Benjamin A. Levinson, PhD

Associate Research Scientist – Division of Biostatistics


Benjamin A. Levinson, PhD, MAEducation:
Benjamin received his PhD from New York University in 2015.

Recent Publications :

Warner E., Liebes L., Levinson B., Downey A., Tiersten A., Muggia F. (2014). Continuous-Infusion Topotecan and Erlotinib: A Study in Topotecan-Pretreated Ovarian Cancer Assessing Shed Collagen Epitopes as a Marker of Invasiveness. The Oncologist. 19(3):250published online:doi:10.1634/theoncologist.2013-0398

Stein S.M.,Tiersten A., Hochster H.S., Blank S.V., Pothuri B., Curtin J., Shapira I., Levinson B., Ivy P., Joseph B., Guddati A.K., and Muggia F. (2013).  A Phase II Study of Oxaliplatin Combined with Continuous Infusion Topotecan for Patients with Previously Treated Ovarian Cancer. International journal of gynecological cancer. 23(9):1577-1582

Wu J., Ryan T., Levinson B., Newman E., Hochster H.S., and Muggia F. (2012). Cisplatin with Capecitabine: Tolerance and Activity in a Phase I/II Study Preferentially Enrolling Patients with Gastric Cancer. Anticancer research. 32: 939-946

Yuan Y., Cohen D., Love E., Yaw M., Levinson B., Nicol S., and Hochster H., (2011). Phase I dose-escalating study of biweekly fixed dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68: 371-378

Safra T., Andreopoulou E.,Levinson B., Borgato L., Pothuri J., Blank S., Tiersten A., Boyd L., Curtin J., and Muggia F. (2010). “Weekly Paclitaxel with Intermittent Imatinib Mesylate (Gleevec): Tolerance and Activity in Recurrent Epithelial Ovarian Cancer”.  Anticancer Research. 30. 3243-3247

Fasano J., Hershman D., Novik Y, Levinson B., Blozie K., and Tiersten A.D. (2010). Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer. Breast Care. 5. 17–21


Contact

 

Additional Information

Phone: 212-263-0321
E-mail: benjamin.levinson@nyumc.org

 

NYULMC Page